Fatima on for Mohit Bansal's questions to Mineralys Therapeutics Inc (MLYS) leadership • Q1 2025
Question
An analyst from Wells Fargo asked for details on plans for subgroup analyses from hypertension trials and their potential to influence physicians and guidelines. She also questioned the 4-week endpoint in the OSA trial and what would be a meaningful and competitive result.
Answer
Executive Jon Congleton stated that data so far shows a profound and predictable response across many subgroups, which is beneficial for prescribers. Chief Medical Officer Dr. David Rodman explained the 4-week OSA endpoint is sufficient to see a benefit on the Apnea Hypopnea Index (AHI). He added that a more important endpoint may be the reduction in nighttime hypertension spikes, where the trial will gather unique data, which could be highly meaningful.